Erratum: Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer

Seviour, Elena G.; Sehgal, Vasudha; Lu, Yingshen; Luo, Zhongguang; Moss, Tyler J.; Zhang, F.; Hill, Steven M.; Liu, W.; Maiti, Sourindra N.; Cooper, Laurence J.N.; Azencot, R.; López-Berestein, Gabriel; Rodríguez-Aguayo, Cristian; Roopaimoole, Rajesha; Pecot, Chad V.; Sood, Anil K.; Mukherjee, Satyam; Gray, Joe W.; Mills, Gordon B.; Ram, Prahlad T.

doi:10.1038/onc.2015.177

Cited by 14 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple studies have shown that there is a notable discordance between genomic information and the actual proteome/phosphoproteome profile, with phosphoprotein information being much more relevant for cancer detection and molecular subtyping. − ,, A recent study published on breast cancer profiling indicated the utility of phosphoproteomic data to help clarify the highly complex genomic features . For example, genomic data have not been successful in treatment decisions with MTOR and PI3K inhibitors due to a myriad of mutations in multiple pathways, most of which are not actionable .…”

Section: Discussionmentioning

confidence: 99%

“…Whereas genetic testing is valuable, it could greatly benefit from an additional layer of biological information. The ability to detect the genome output, active proteins, can provide useful real-time information about the organism’s physiological functions and disease progression, in particular, in cancer. − Oncologists understand the value of protein testing and immunoassays and can easily interpret the results. Compared with gene panel testing, immunoassays, once developed, are relatively inexpensive and are easier to adopt in clinical settings.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Plasma-Derived Extracellular Vesicle Phosphoproteomics through Chemical Affinity Purification

Iliuk

et al. 2020

J. Proteome Res.

View full text Add to dashboard Cite

Invasive nature and pain caused to patients inhibit the routine use of tissue biopsy-based procedures for cancer diagnosis and surveillance. The analysis of extracellular vesicles (EVs) from biofluids have recently gained significant traction in the liquid biopsy field. EVs offer an essential "snapshot" of their precursor cells in real time and contain information-rich collection of nucleic acids, proteins, lipids, etc.The analysis of protein phosphorylation, as a direct marker of cellular signaling and disease progression, could be an important stepstone to successful liquid biopsy applications. Here, we introduce a rapid EV isolation method based on chemical affinity called EVtrap (Extracellular Vesicles Total Recovery and Purification) for EV phosphoproteomics analysis of human plasma. Incorporating EVtrap with high performance mass spectrometry (MS), we were able to identify over 16,000 unique peptides representing 2,238 unique EV proteins from just 5 μL plasma sample, including most known EV markers, with substantially higher recovery levels compared to ultracentrifugation. Most importantly, more than 5,500 unique phosphopeptides representing almost 1,600 phosphoproteins in EVs were identified using only 1 mL of plasma. Finally, we carried out quantitative EV phosphoproteomics analysis of plasma samples from patients diagnosed with chronic kidney disease or kidney cancer, identifying dozens of phosphoproteins capable of distinguishing disease states from healthy controls. The study demonstrates the potential feasibility of our robust analytical pipeline for cancer signaling monitoring by tracking plasma EV phosphorylation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Plasma-Derived Extracellular Vesicle Phosphoproteomics through Chemical Affinity Purification

Iliuk

et al. 2020

J. Proteome Res.

View full text Add to dashboard Cite

show abstract

“…Since the discovery of miRNAs, many miRNAs have been found to have different expression patterns in different diseases, that are regulated by mechanisms as varied as the presence of deletions, amplifications or mutations involving miRNA loci, epigenetic silencing or the dysregulation of transcription factors that target specific miRNAs ( 26 , 27 ).…”

Section: Discussionmentioning

confidence: 99%

miR-199a-3p is involved in the pathogenesis and progression of diabetic neuropathy through downregulation of SerpinE2

Liu

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

The present study aimed to investigate the expression status of miRNA-199a-3p in patients with diabetic neuropathy (DN) and the mechanism by which this miRNA is involved in the genesis of DN. The expression of miRNA-199a-3p in plasma of peripheral blood was compared between patients with diabetes and a family history of diabetes and control volunteers by reverse transcription-quantitative polymerase chain reaction (RT-qPCR); in 60 diabetes patients, 45 (75%) demosntrated upregulated miR-199a-3p expression compared with control volunteer plasma. RT-qPCR was also used to detect miRNA-199a-3p expression in paired lower limb skin tissues from 30 patients with DN and 20 control volunteers; miR-199a-3p expression in patients with DN was significantly higher than in the control group. Next miR-199a-3p expression levels were evaluated with respect to the clinic-pathological parameters of diabetes; increased expression of miR-199a-3p was significantly associated with increased disease duration (P=0.041), glycated hemoglobin (HbA1C) levels (P=0.033), and fibrinogen levels (P=0.003). Finally, the effects on downstream mRNA expression levels were investigated as a result of manipulating miR-199a-3p levels. miR-199a-3p overexpression inhibited the expression of the extracellular serine protease inhibitor E2 (SerpinE2). Therefore, it may be hypothesized that miR-199a-3p can induce DN via promoting coagulation in skin peripheral circulation, through the downregulation of SerpinE2. The present findings suggested that miR-199a-3p may have potential as a novel therapeutic target for the treatment of patients with DN.

show abstract

Regulation of Non-coding RNAs in Cardiometabolic Tissues and Tumors

Holvoet

2021

Non-Coding RNAs at the Cross-Road of Cardiometabolic Diseases and Cancer

View full text Add to dashboard Cite

Erratum: Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer

Cited by 14 publications

References 0 publications

Plasma-Derived Extracellular Vesicle Phosphoproteomics through Chemical Affinity Purification

Plasma-Derived Extracellular Vesicle Phosphoproteomics through Chemical Affinity Purification

miR-199a-3p is involved in the pathogenesis and progression of diabetic neuropathy through downregulation of SerpinE2

Regulation of Non-coding RNAs in Cardiometabolic Tissues and Tumors

Contact Info

Product

Resources

About